Biorasi latest CRO to join Medidata's Rave party
The Miami, Florida-based contract research organisation (CRO) became the latest company to sign up to the Medidata Rave electronic data capture (EDC), management and reporting system last week, with the CRO saying the cloud-based technology would be used across its Phase I-IV global clinical trials.
According to Chairman Boris Reznik, the platform will work alongside Biorasi’s TALOS technology which is a set of tools that standardises the CRO’s processes, workflow, reporting and training content, as well as integrating systems and teams, and optimizing study design and trial management.
“Biorasi’s adoption of Rave has greatly benefited our clinical trials process. The dynamic, easy-to-use technology offers our platform TALOS the power to do more compared to other EDC systems,” he said.
Growth
The firm added the technology will allow sponsors to gain the advantages of a multi-dimensional, full suite of Medidata products to optimize clinical trial operations and save costs, especially as the CRO looks to continue growing following the acquisition of fellow CRO Advanced Biosciences Research last December.
“We plan to double in growth this year due to the rising demand of Biosimilars and Interchangeables studies from leading pharmaceutical companies around the world,” said Reznik. “Utilizing enterprise suite technology allows us to fully leverage our core competency of trial optimization.”
In 2014, Medidata saw its customer base increase 22% on the previous year, the majority of which were CROs signing increasingly “strategic and meaningful” relationships, management said in February.
With Biorasi becoming the latest CRO to sign up to the Rave system, Medidata’s SVP of Global Partner Business, Pat Bernard said his firm “can support Biorasi’s mission of developing and implementing groundbreaking methods of optimizing clinical research with the scalable, flexible and easily configurable nature of the Medidata Clinical Cloud and help Biorasi in its innovative efforts to deliver successful new treatments for time-critical indications.”
